Company profile - Nanjing King-Friend

Kingfriend Overview

Nanjing Kingfriend integrates drug research and development, production and sales.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF), headquartered in Nanjing, China, is a leading global biopharmaceutical enterprise dedicated to building an integrated platform for internationalization of its high-end injectables and to serve domestic pharmaceutical manufacturers in expanding their business around the globe. With over a dozen of ANDAs approved in US each year, NKF has grown into one of the biggest suppliers of high-end injectables in the US. NKF is also one of the biggest suppliers of Heparin APIs and finished dosage forms, and is actively working with partners from over 60 countries for over 80 USFDA approved products.

Total ANDA approvals

New ANDA approvals obtained each year

FDA-compliant high-speed isolator production line

Annual declaration of products to FDA

Cumulative number of FDA inspection passed

The Global Industry Layout

We establish efficient, integrated and open project management systems for global pharmaceutical companies

Nanjing Headquarter

R&D Center
Development, production and commercial manufacturing of small molecule injectables

Drug development and commercialization based on mRNA technology

Treatment based on nucleic acid detection technology (mRNA)
Bioinformatics determination of target molecules
platform for mRNA in vitro synthesis and modification
Drug delivery system development
Cheng Du

R&D center
Hydro-acupuncture and lyophilization product line

Monoclonal antibody-based drugs (mAb)

Early research and development of monoclonal antibody
Commercial development monoclonal antibodies
Chicago, USA

Global Clinical Research Center
U.S. Marketing

Milestones

Over the past 30 years, we have been refreshing our goals and making positive progress.

2023

License-in 3 top selling Insulins

2022

57 ANDA approvals obtained in total

pipeline expansion at a rate of 10 new projects per year

2021

Establishment of Bio-innovative Business Department

Improved R&D capabilities and entered the field of biologics

2019

Acquisition of US pharmaceutical company Meitheal

Broadened the global market of preparations and completed the coverage of the industry chain

2016

Acquisition of Chengdu Jianjin Pharmaceutical

Full set of FDA-compliant GMP workshop

audited by the FDA

2014

Passed CFDA GMP inspection

Obtained three domestic approvals and started filling with ANDA

2011

Construction of Nanjing FDF plant started

The world’s top FDF plant

2004

Launch of enoxaparin, nadroparin and dalteparin preparation projects

Initiated the development and declaration of heparin-based APIs and preparations

2000

Establishment of Nanjing Kingfriend Biochemical Pharmaceutical Co, Ltd

Ventured into pharmaceutical export business

1991

Establishment of Nanjing Kingfriend Chemical Biopharmaceutical Factory

Rapid development in heparin industry

1987

Involvement in the field of heparin sodium

Pioneer in the heparin industry in China